Back in October of last year, Anil Kapur - Executive Vice President of Corporate Strategy and CCO at Geron Corporation joined the BOD at Verastem Oncology.
https://talent4boards.com/verastem-onco ... directors/
https://www.verastem.com/about-us/leade ... -directors
Two points of interest here.....well maybe one, the other perhaps just coincidence.
First one: both Verastem and Geron are focused on treating cancer in patients with unmet needs.
"At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address areas of high unmet need in RAS pathway-driven cancers.
Our focus is on bringing new and better treatment options to patients who are battling these cancers—such as low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer. These types of cancer are extremely difficult to treat, and there are limited effective therapeutic options available. That means many patients run out of options and time. We’re committed to changing that."
Second: the look of the Verastem website seems awfully familiar...... maybe it's just me? -Kmall
https://www.geron.com/
Anil Kapur's side hustle.......
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam